Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
608.8 INR | +5.06% | +3.70% | +20.68% |
May. 14 | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
May. 13 | Aarti Pharmalabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Sales 2022 | 12K 999K | Sales 2023 | 19.45K 1.62M | Capitalization | 25B 2,081B |
---|---|---|---|---|---|
Net income 2022 | 1.22B 102B | Net income 2023 | 1.94B 161B | EV / Sales 2022 * | - |
Net Debt 2022 | 2.58B 215B | Net Debt 2023 | 1.52B 127B | EV / Sales 2023 | 1,363,395 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
12.9
x | Employees | 2,042 |
Yield 2022 * |
-
| Yield 2023 |
0.73% | Free-Float | 52.07% |
1 day | +2.85% | ||
1 week | +1.52% | ||
Current month | +16.15% | ||
1 month | +15.55% | ||
3 months | +13.41% | ||
6 months | +50.95% | ||
Current year | +18.14% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 22-10-16 | |
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 22-10-16 |
Piyush Lakhani
DFI | Director of Finance/CFO | - | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 22-10-16 |
Chairman | 49 | 21-08-06 | |
Director/Board Member | 77 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 608.8 | +5.06% | 2 889 058 |
24-05-21 | 579.4 | -5.80% | 371,707 |
24-05-18 | 615.2 | +0.19% | 76,816 |
24-05-17 | 614 | +1.05% | 473,046 |
24-05-16 | 607.6 | +3.51% | 1,334,391 |
Delayed Quote NSE India S.E., May 22, 2024 at 02:26 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+18.14% | 631M | |
+37.78% | 723B | |
+32.82% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.64% | 244B | |
-4.13% | 208B | |
+10.63% | 210B | |
+9.32% | 169B |
- Stock Market
- Equities
- AARTIPHARM Stock